A retrospective observational real-world study assessing the efficacy, safety and management of emerging toxicities in daily clinical practice in patients of relapsed/refractory Multiple Myeloma treated with Carfilzomib–lenalidomide–dexamethasone (KRd) in Italy
Latest Information Update: 16 Mar 2021
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2021 New trial record
- 01 Feb 2021 Results published in the Hematological Oncology